Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity
Open accessAbstract
Summary: Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health‐related quality of life (HRQoL) than those receiving placebo. The current study extends these findings by examining 3‐year changes in HRQoL. HRQoL was assessed using the obesity‐specific Impact of Weight on Quality of Life‐Lite (IWQOL‐Lite) questionnaire, as well as the Short‐Form 36 v2 (SF‐36) health survey. At 3 years, mean change (±standard deviation) in IWQOL‐Lite total score from baseline for liraglutide (n = 1472) was 11.0 ± 14.2, vs. 8.1 ± 14.7 for placebo (n = 738) (estimated treatment difference [ETD] 3.4 [95% confidence interval (CI): 2.0, 4.7], P < 0.0001). Mean change in SF‐36 physical component summary (PCS) score from baseline for liraglutide was 3.1 ± 7.3, vs. 2.6 ± 7.6 for placebo (ETD 0.87 [95% CI: 0.17, 1.6], P = 0.0156). Mean change in SF‐36 mental component summary score did not significantly differ between groups. Both IWQOL‐Lite total score and PCS score demonstrated an association between greater HRQoL improvement with higher weight loss. Liraglutide 3.0 mg was also associated with improved health utility (Short‐Form‐6D and EuroQol‐5D, mapped from IWQOL‐Lite and/or SF‐36) vs. placebo. Liraglutide 3.0 mg, plus diet and exercise, is associated with long‐term improvements in HRQoL with obesity or overweight with comorbidity vs. placebo.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
When older adults lose weight under supervision, their physical function and quality of life outcomes improve.
“When older adults lose weight under supervision, their physical function and QoL outcomes improve [48, 49].”
From Obesity pharmacotherapy in older adults: a narrative review of evidence (2025) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369 · see citing works
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855 · see citing works
The estimation of a preference-based measure of health from the SF-36.
Brazier, J., Roberts, J., & Deverill, M. (2002) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00130-8 · Cited by 3,164 · see citing works
Basevi, V., Mario, S. D., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,058 · see citing works
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
Self-citationStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240 · see citing works
User’s manual for the SF-12v2 health survey
Ware, J., Kosinski, M., Bowker, D., Gandek, B., Ware, J. E., & Turner‐Bowker, D. M. (2002) · Cited by 1,085 · see citing works
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · see citing works
Self-citationDeriving a Preference-Based Single Index from the UK SF-36 Health Survey
Brazier, J. E., Usherwood, T. P., Harper, R., & Thomas, K. J. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00103-6 · Cited by 686 · see citing works
Development of a brief measure to assess quality of life in obesity
Kolotkin, R. L., Crosby, R. D., Kosloski, K. D., & Williams, G. R. (2001) · Obesity Research · doi:10.1038/oby.2001.13 · Cited by 641 · see citing works
Kolotkin, R. L., & Andersen, J. R. (2017) · Clinical Obesity · doi:10.1111/cob.12203 · Cited by 590 · see citing works
Self-citationKolotkin, R. L., & Crosby, R. D. (2002) · Quality of Life Research · doi:10.1023/a:1015081805439 · Cited by 352 · see citing works
Self-citationUl‐Haq, Z., Mackay, D. F., Fenwick, E., & Pell, J. P. (2013) · Obesity · doi:10.1002/oby.20107 · Cited by 311 · see citing works
The Relationship between Health‐Related Quality of Life and Weight Loss
Kolotkin, R. L., Crosby, R. D., Williams, G. R., Hartley, G. G., & Nicol, S. E. (2001) · Obesity Research · doi:10.1038/oby.2001.73 · Cited by 280 · see citing works
Self-citationWarkentin, L. M., Das, D., Majumdar, S. R., Johnson, J. A., & Padwal, R. S. (2013) · Obesity Reviews · doi:10.1111/obr.12113 · Cited by 202 · see citing works
Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?
Rowen, D., Brazier, J., & Roberts, J. (2009) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-7-27 · Cited by 193 · see citing works
An integrated method to determine meaningful changes in health-related quality of life
Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.04.004 · Cited by 166 · see citing works
Self-citationWarkentin, L. M., Majumdar, S. R., Johnson, J. A., Agborsangaya, C. B., Rueda‐Clausen, C. F., Sharma, A. M., Klarenbach, S. W., Karmali, S., Birch, D. W., & Padwal, R. S. (2014) · BMC Medicine · doi:10.1186/s12916-014-0175-5 · Cited by 133 · see citing works
Maciejewski, M. L., Patrick, D. L., & Williamson, D. F. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.015 · Cited by 128 · see citing works
Kroes, M., Osei-Assibey, G., Baker-Searle, R., & Huang, J. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1128403 · Cited by 121 · see citing works
Impact of Weight Loss and Regain on Quality of Life: Mirror Image or Differential Effect?
Engel, S. G., Crosby, R. D., Kolotkin, R. L., Hartley, G. G., Williams, G. R., Wonderlich, S. A., & Mitchell, J. E. (2003) · Obesity Research · doi:10.1038/oby.2003.166 · Cited by 76 · see citing works
Self-citationKim, S.-K., Kim, S.-H., Jo, M., & Lee, S. (2015) · Health and Quality of Life Outcomes · doi:10.1186/s12955-015-0227-3 · Cited by 65 · see citing works
Brazier, J. E., Kolotkin, R. L., Crosby, R. D., & Williams, G. R. (2004) · Value in Health · doi:10.1111/j.1524-4733.2004.74012.x · Cited by 63 · see citing works
Self-citationKolotkin, R. L., Fujioka, K., Wolden, M. L., Brett, J. H., & Bjorner, J. B. (2016) · Clinical Obesity · doi:10.1111/cob.12146 · Cited by 40 · see citing works
Self-citationObesity Drug Outcome Measures: Results of a Multi-Stakeholder Critical Dialogue
Kahan, S. I., Ferguson, C. C., David, S., et al. (2013) · Current Obesity Reports · doi:10.1007/s13679-013-0052-0 · Cited by 9 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [27]Bays HE, Pi‐Sunyer FX, Uddén Hemmingsson J et al Liraglutide 3.0 mg: weight‐loss dependent and independent effects. Endocr Rev 2015; 5(Suppl. 2) Abstract FRI‐551. URL: http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2015.OABA.8.FRI-551 (accessed 2 Sept 2017). · DOI
Cited by
Sorted by citations
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151 · see citing works
Horn, D. B., Almandoz, J. P., & Look, M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2051366 · Cited by 114 · see citing works
Obesity pharmacotherapy in older adults: a narrative review of evidence
Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01529-z · Cited by 51 · see citing works
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
O’Neil, P. M., & Rubino, D. M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2150006 · Cited by 19 · see citing works
Kushner, R. F., Johansen, O. E., Araujo Torres, K., Phan, T.-M., & Marczewska, A. (2025) · Obesities · doi:10.3390/obesities5020029 · Cited by 5 · see citing works
- Authors
- Kolotkin, R. L., Smolarz, B. G., Meincke, H. H., & Fujioka, K.
- Affiliations
- Western Norway University of Applied Sciences (NO)
- Novo Nordisk Inc. Plainsboro NJ USA
- Novo Nordisk (Denmark) (DK)
- Scripps Clinic (US)
- Corresponding author
- Kolotkin, R. L.
- Venue
- Clinical Obesity
- Publisher
- Wiley
- Published
- 2017-10-16
- Volume
- 8
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1758-8103 (ISSN-L)
- 1758-8111
- PMC
- PMC5813214
- OpenAlex
- W2765836278
- Cited by
- 46
- References
- 25
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 4 · 2023: 9 · 2022: 5 · 2021: 11 · 2020: 2 · 2019: 2 · 2018: 1
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Obesity (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by-nc-nd)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- liraglutide, health-related quality of life, obesity, overweight, prediabetes, weight loss, IWQOL-Lite, SF-36, health utility, GLP-1 receptor agonists, long-term outcomes, diet and exercise
- MeSH terms
- Liraglutide, Adolescent, Adult, Aged, Double-Blind Method, Female, Health Status, Humans, Male, Mental Health, Middle Aged, Obesity, Quality of Life, Surveys and Questionnaires, Time Factors, Weight Loss, Treatment Outcome, Cost of Illness, Anti-Obesity Agents, Incretins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
